AUTHOR=Lin Ida , Rupert Peter B. , Pilat Kristina , Ruff Raymond O. , Friend Della J. , Chan Man Kid , Clarke Midori , Hoffstrom Benjamin G. , Carter Jane , Meshinchi Soheil , Bandaranayake Ashok D. , Mehlin Christopher , Olson James M. , Strong Roland K. , Correnti Colin E. TITLE=Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics JOURNAL=Frontiers in Drug Discovery VOLUME=3 YEAR=2023 URL=https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2023.1216516 DOI=10.3389/fddsv.2023.1216516 ISSN=2674-0338 ABSTRACT=

Mesothelin is a glypiated, cell-surface glycoprotein expressed at low levels on normal mesothelium but overexpressed by many cancers. Implicated in cell adhesion and multiple signaling pathways, mesothelin’s precise biological function and overall structure remain undefined. Antibodies targeting mesothelin have been engineered into immunotoxins, antibody-drug conjugates, CAR-T cells, or bispecific T cell engagers as candidate therapeutics but most face challenges, including binding epitopes that are not optimal for selected modalities. Here we describe the isolation and characterization of a novel anti-mesothelin antibody, 1A12, including crystallographic mapping of the 1A12 epitope in relation to other antibodies (amatuximab, anetumab). 1A12 possesses uniquely favorable properties, including a membrane-proximal epitope, and enabled structure determination of the complete mesothelin ectodomain. We incorporated 1A12 into two different bispecific T cell engaging architectures with various anti-CD3 co-targeting elements as candidate therapeutics, demonstrating in vitro functionality and potency.